Laurent Arthaud - Cellectis Director
| ALCLS Stock | EUR 2.60 0.16 6.56% |
Director
Mr. Laurent Arthaud has served as NonExecutive Independent Director of Cellectis SA since October 2011. From 2006 to 2012, Mr. Arthaud held the position of Deputy Chief Executive Officer at CDC Entreprises. From 2009 he also directed InnoBio, an investment fund managed by Bpifrance Investissement as part of the FSI France Investissement program. From 1999 to 2004 he served as Vice President of Aventis Capital, an investment subsidiary of the pharmaceuticals group Aventis, and as President of Pharmavent Partners from 2004 to 2006. Mr. Arthaud is a graduate of the Ecole Polytechnique and the lEcole Nationale de Statistique et dAdministration Economique. He is currently on the Board of Directors of Adocia, TxCell, Calyxt Inc. and Aledia, among others. since 2011.
| Age | 54 |
| Tenure | 13 years |
| Phone | 33 1 81 69 16 00 |
| Web | https://www.cellectis.com |
Cellectis Management Efficiency
The company has return on total asset (ROA) of (0.2408) % which means that it has lost $0.2408 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.557) %, meaning that it generated substantial loss on money invested by shareholders. Cellectis' management efficiency ratios could be used to measure how well Cellectis manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | -0.56 | |||
| Return On Asset | -0.24 |
Cellectis Leadership Team
Elected by the shareholders, the Cellectis' board of directors comprises two types of representatives: Cellectis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cellectis. The board's role is to monitor Cellectis' management team and ensure that shareholders' interests are well served. Cellectis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cellectis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stephane Depil, Senior Vice President - Research and Development and Chief Medical Officer | ||
| Elsy Boglioli, Executive Vice President - Strategy and Corporate Development | ||
| Dr MBA, Chief Officer | ||
| Thierry Moulin, CFO | ||
| Eric Dutang, CFO, Member of the Executive Committee | ||
| Laurent Arthaud, Director | ||
| Valerie Cros, Principal Officer | ||
| Mathieu Simon, Member of the Executive Committee, Senior Vice President | ||
| Andre Choulika, Chairman of the Board and CEO, Member of the Executive Committee | ||
| MarieBleuenn Terrier, General Counsel, Member of the Executive Committee | ||
| Kyung NamWortman, Ex Officer | ||
| Stefan Scherer, Senior Vice President Clinical Development and Deputy Chief Medical Officer | ||
| Jean Epinat, Chief Officer | ||
| Pierre Bastid, Director | ||
| William Monteith, Senior Vice President U.S. Manufacturing | ||
| Philippe Duchateau, Chief Scientific Officer | ||
| Pascalyne Wilson, Director Communications | ||
| Alain Godard, Advisor, Independent Director and Member of Compensation Committee | ||
| Herve Hoppenot, Non-Executive Independent Director | ||
| Annick Schwebig, Director | ||
| David Sourdive, Co-Founder, Executive VP of Corporate Devel. and Director | ||
| Rainer Boehm, Non-Executive Independent Director | ||
| Stephan Reynier, Chief Regulatory and Compliance Officer, Member of the Executive Committee | ||
| MSc MSc, Chief Officer | ||
| JeanMarie Messier, Independent Director |
Cellectis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cellectis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.56 | |||
| Return On Asset | -0.24 | |||
| Operating Margin | (6.01) % | |||
| Current Valuation | 78.42 M | |||
| Shares Outstanding | 55.59 M | |||
| Shares Owned By Institutions | 21.25 % | |||
| Price To Earning | (14.84) X | |||
| Price To Book | 0.77 X | |||
| Price To Sales | 4.34 X | |||
| Revenue | 57.29 M |
Pair Trading with Cellectis
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cellectis position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cellectis will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Cellectis could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cellectis when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cellectis - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cellectis to buy it.
The correlation of Cellectis is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cellectis moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cellectis moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cellectis can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cellectis. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for Cellectis Stock analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |